Ratings Caplin Point Laboratories Limited

Equities

CAPLIPOINT

INE475E01026

Delayed Bombay S.E. Other stock markets 05:32:38 2024-06-26 EDT			5-day change	1st Jan Change
1,379 ^INR	-1.67%		-1.56%	+1.67%

06-11	Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer	CI
05-24	Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	MT

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 51% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The firm trades with high earnings multiples: 23.42 times its 2024 earnings per share.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CAPLIN POINT LABORATORIES LIMITED	+1.67%	1.28B		C
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.55%	43.29B		B-
OTSUKA HOLDINGS CO., LTD.	+27.64%	22.38B		B+
SANDOZ GROUP AG	+19.84%	15.51B		-
CIPLA LIMITED	+18.71%	14.52B		B+
ZYDUS LIFESCIENCES LIMITED	+54.83%	12.93B		B
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
ONO PHARMACEUTICAL CO., LTD.	-11.39%	6.56B		B+
ASPEN PHARMACARE HOLDINGS LIMITED	+17.73%	5.87B		B+
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes